Elanco, Starpharma ink deal to develop new animal-health products

Greenfield, Ind.

-- Elanco Animal Health signed a deal with Australia-based Starpharma Holding Limited this week to collaborate on the development of new animal-health products.

The collaborative research, license and commercialization agreement gives Elanco access to Starpharma’s dendrimer technology. Dendrimers are considered a unique class of polymers that play a role in nanotechnology as carrier molecules and building blocks.

Under the agreement, Starpharma will receive revenue from research fees and is eligible for milestone payments and royalties on the sale of any product developed, the companies say in a prepared statement. Elanco will receive exclusivity within the animal-health field. Terms were not disclosed.

Starpharma retains all rights to use the technology outside Elanco's specific field of interest, including all uses in humans, and continues to work to add to its portfolio of partners for drug delivery and dendrimer technology more widely.